4D Molecular Therapeutics Gross Profit

The latest gross profit for FDMT is $40M as of June 2026. That compares with $1.3M in the prior-year period — up 2852.7% year over year. That is below the Healthcare sector average of $65B. Investors often review this figure alongside 4D Molecular Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, FDMT's gross profit moved from $1.3M to $40M — a 2852.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in 4D Molecular Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, FDMT currently prints $40M for gross profit, while the sector average sits near $65B. That is roughly 99.9% below the sector mean. Large gaps often invite a closer look at 4D Molecular Therapeutics's growth, margins, and balance sheet.

A gross profit figure of $40M for FDMT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $65B. Explore the charts below for those layers of context.

After noting FDMT's gross profit ($40M), review year-over-year change from $1.3M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.